Table 1.

Baseline clinical and serologic characteristics of the patients with ANCA-associated systemic vasculitis and renal failurea

Clinical and Laboratory Features at EntryIntravenous Methylprednisolone (n = 67)Plasma Exchange(n = 70)Total(n = 137)P
Age (yr; median [range])66 (27 to 81)67 (28 to 79)66 (27 to 81)0.93
Female gender (n [%])24 (36)29 (41)53 (38.7)0.50
Wegener's granulomatosis/microscopic polyangiitis (n [%])24/43 (35.8/64.2 8)18/52 (25.7/74.3)42/95 (30.7/69.3)0.20
Nonoliguric/dialysis requiring (n [%])19/48 (28.4/71.6)23/47 (32.9/67.1)42/95 (30.7/69.3)0.57
PR3-ANCA (n [%])31 (46.3)26 (37.1)57 (42.6)0.35
MPO-ANCA (n [%])31 (46.3)40 (57.1)71 (51.9)
ANCA negative (n [%])3 (4.5)4 (5.7)7 (5.3)
BVAS21 (12 to 41)21 (12 to 39)21 (12 to 41)0.69
Vasculitis Damage Index (median [range])0 (0 to 4)0 (0 to 7)0 (0 to 7)0.86
Creatinine (μmol/L; median [range])718 (498 to 1566)754 (500 to 1669)735 (498 to 1669)0.96
C-reactive protein (mg/L; median [range])108 (2 to 264)76 (7 to 281)93 (2 to 281)0.23
Erythrocyte sedimentation rate (mm/h; median [range])84 (2 to 150)94 (20 to 140)89 (2 to 150)0.34
  • a ANCA, autoantibodies to neutrophil cytoplasmic antigens; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; PR3, proteinase 3.